| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 | 4,356 | 4,240 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 | 3,472 | 3,633 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 | 884 | 607 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % | 19 % | 12 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 | 39 | -16 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 | 0.66 | 1.08 |
Biocon
Biocon
368.55
-14.05
(-3.67%)
Market Cap
59,738.60 Cr
PE Ratio
94.94
Volume
20,08,502.00
Day High - Low
379.90 - 366.25
52W High-Low
424.95 - 299.00
Key Fundamentals
Market Cap
59,738.60 Cr
EPS
8.46
PE Ratio
94.94
PB Ratio
1.58
Book Value
233.84
EBITDA
4,374.50
Dividend Yield
0.10 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
5.16
Debt to Equity
0.84
Analyst Rating and Forecast
- By Refinitiv from14 analysts
Actual
Company News
View All News
Biocon Pharma Limited receives U.S. FDA approval for Liraglutide Injection ANDA, strengthening the company's complex drug portfolio following recent Saxenda approval.
Biocon Limited reported consolidated revenue of ₹41,730 million for Q3FY26, up 9.2% YoY. Net profit attributable to shareholders reached ₹1,438 million with EPS of ₹1.08.
FDA Eases Rules for Biosimilar Drug Makers
10 days ago
10 days agoThe FDA has reduced regulatory requirements for companies developing cheaper versions of expensive biologic drugs, potentially benefiting biosimilar manufacturers like Biocon.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,744.40 | #1 4,18,540.00 | 38.21 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 46.21 | |
5,972.50 | 1,58,551.10 | 64.01 | 9,712.00 | 18.67 | 2,191 | -1.02 | 35.70 | |
4,210.80 | 1,42,512.60 | 62.70 | 11,539.40 | 6.99 | 1,911 | 26.24 | 44.98 | |
1,274.50 | 1,06,373.60 | 19.25 | 33,741.20 | 16.73 | 5,725 | -15.28 | 47.17 | |
2,251.50 | 1,02,848.30 | 22.06 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 45.75 | |
1,239.20 | 1,00,099.10 | 22.07 | 28,409.50 | 7.12 | 5,291 | -57.18 | 24.80 | |
876.15 | 88,161.20 | #1 17.54 | 23,511.00 | 18.55 | 4,615 | -0.32 | 40.05 | |
2,000.80 | 82,594.00 | 45.82 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 37.28 | |
1,247.50 | 72,455.00 | 20.80 | 32,345.60 | 9.43 | 3,484 | 7.59 | 53.16 | |
5,240.00 | 62,652.10 | 25.87 | 13,458.30 | 3.70 | 2,216 | 1.90 | 36.58 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,823 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Equity & Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,038 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,448 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jan 2026 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % | 54.45 % | 54.45 % | 44.91 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % | 6.61 % | 7.39 % | 7.14 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % | 22.10 % | 21.71 % | 24.16 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % | 12.71 % | 12.38 % | 10.23 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % | 4.12 % | 4.06 % | 13.55 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 | 4,13,191 | 3,94,279 | 3,94,215 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 | 0.00 |
| Dividend Yield (%) | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.14 | 0.00 |
Announcements
Notification To Stock Exchanges7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-AcquisitionMar 03, 2026
Mar 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Mar 02, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2026
Feb 12, 2026Outcome Of Board Meeting - In-Principle Approval Of AcquisitionFeb 12, 2026
Feb 12, 2026Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Board Meeting Outcome for Outcome Of Board Meeting- Quarterly ResultsFeb 12, 2026
Feb 12, 2026Outcome Of Board Meeting-Financial ResultsFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2026
Feb 07, 2026Buyback Of Commercial PapersJan 30, 2026
Jan 30, 2026Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanyJan 28, 2026
Jan 28, 2026Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanyJan 28, 2026
Jan 28, 2026Notification To Stock ExchangesJan 28, 2026
Jan 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2026
Jan 28, 2026Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Ddhspod/
P/CIR/2025/0000000137 Dated October 15 2025Jan 21, 2026
Jan 21, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJan 21, 2026
Jan 21, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 20, 2026
Jan 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 15, 2026
Jan 15, 2026Announcement under Regulation 30 (LODR)-AllotmentJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Board Meeting Intimation for Intimation For The Board Meeting And Earnings Conference Call For Analysts And InvestorsJan 13, 2026
Jan 13, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 12, 2026
Jan 12, 2026Intimation Of Approval Of Unaudited Condensed Consolidated Interim Financial StatementsJan 12, 2026
Jan 12, 2026Notification To Stock ExchangesJan 12, 2026
Jan 12, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Intimation Of Record Date For Commercial PaperJan 08, 2026
Jan 08, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 06, 2026
Jan 06, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 06, 2026
Jan 06, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJan 05, 2026
Jan 05, 2026Announcement under Regulation 30 (LODR)-AllotmentJan 05, 2026
Jan 05, 2026Intimation Of Early Full Redemption Of Ncds By The CompanyJan 05, 2026
Jan 05, 2026Issue Of Commercial Papers Of Rs. 200 CroresJan 02, 2026
Jan 02, 2026Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 01, 2026
Jan 01, 2026Shareholder Meeting / Postal Ballot-Outcome of EGMDec 31, 2025
Dec 31, 2025Closure of Trading WindowDec 26, 2025
Dec 26, 2025Intimation Of Record Date For Commercial PaperDec 24, 2025
Dec 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 23, 2025
Dec 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 23, 2025
Dec 23, 2025Issue Of Commercial PapersDec 22, 2025
Dec 22, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 38.22
ATR(14)
Volatile 10.70
STOCH(9,6)
Neutral 31.05
STOCH RSI(14)
Oversold 8.19
MACD(12,26)
Bearish -2.33
ADX(14)
Weak Trend 21.45
UO(9)
Bearish 35.05
ROC(12)
Downtrend And Accelerating -5.00
WillR(14)
Oversold -93.71
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology,...more
Listing Date
07 Apr, 2004(21 Years,
41 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
